MCL is a rare disease and for various reasons not every question can be addressed in a
clinical trial. Registry data can help to evaluate open questions by collecting real world information about treatments and disease courses. At this time the registry focusses on patients considered to suffer from so called indolent MCL or patients with relapsed disease receiving second line treatment with a novel targeted agent.
Wissenschaftliche und kooperative Projekte
Analysis of clinical outcomes of patients with relapsing/refractory Mantle Cell Lymphoma in Switzerland – SCHOLAR-CH
Status: Active
Type, Partner: Entity, Kite/Gilead, SAKK
Year: 2022
Type of analysis: Aggregated
Real-world Results of Brexucabtagene Autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma – First German/Swiss Analysis
Status: Active
Type, Partner: Academic, EMCL Network
Year: 2022-2024
Type of analysis: Aggregated
Real-world effectiveness and safety of brexucabtagene autoleucel versus patient-individual therapy in relapsed/refractory Mantle Cell Lymphoma: A European Mantle Cell Lymphoma Network (EMCL) registry study mandated by the G-BA
Status: Active
Type, Partner: Entity, Kite/Gilead
Year: 2023
Type of analysis: Aggregated
Results of Pirtobrutinib in the real world setting – an EMCL initiative
Status: Active
Type, Partner: Entity and Academic, Lilly and the EMCL Network
Year: 2024
Type of analysis: Aggregated
Real-world results of radiotherapy for patients with Mantle Cell Lymphoma – a European Analysis
Status: Active
Type, Partner: Academic, EMCL Network
Year: 2024
Type of analysis: Aggregated
Sarcopenia in Mantle Cell Lymphoma after chemoimmunotherapy – A retrospective analysis from the EMCL-R
Status: Active
Type, Partner: Academic, EMCL Network
Year: 2023
Type of analysis: Aggregated
Evolution of TP53 alterations during the disease course of MCL and impact on prognosis
Status: Active
Type, Partner: Academic, EMCL Network
Year: 2024
Type of analysis: Aggregated
Healthcare Resource utilization study for an Autologous Stem Cell Transplantation (ASCT) in 1L Mantel Cell Lymphoma (MCL)
Status: Active
Type, Partner: Entity, Janssen
Year: 2024
Type of analysis: Aggregated
Outcomes of Subsequent Anti-Lymphoma Therapies in patients with Mantle Cell Lymphoma treated after chimeric antigen receptor (CAR) T-cell therapy vs. SOC in the Real-world setting in Europe – A prospective analysis
Status: In activation
Type, Partner: Academic, EMCL Network
Year: 2024
Type of analysis: Aggregated
Clinical long-term follow-up of patients after completion of the EMCL Network TRIANGLE phase III trial: Impact of subsequent treatment lines and risk factors on the long term results of overall survival – MULTIPLY
Status: In activation
Type, Partner: Academic, EMCL Network
Year: 2024
Type of analysis: Aggregated
Molecular characterization of patients with early POD
Status: In activation
Type, Partner: Academic, EMCL Network
Year: 2024
Type of analysis: Aggregated
EU-Real-world analysis of outcomes of second line therapy in R/R MCL patients
Status: In activation
Type, Partner: Academic, EMCL Network
Year: 2024
Type of analysis: Aggregated
Use of Lenalidomide in MCL treatment
Status: Completed
Type, Partner: Entity, Celgene
Year: 2017+
Key parameters: Number of patients treated with Lenalidomide for MCL
Type of analysis: Aggregated, Contact to treatment centers using drug
Treatment trends in MCL
Status: Completed
Type, Partner: Entity, Janssen
Year: 2019+
Type of analysis: Aggregated
Real-world survival, treatment patterns and healthcare resource utilization among patients with relapsed/refractory Mantle Cell Lymphoma in Europe – SCHOLAR 2
Status: Completed
Type, Partner: Entity, Gilead
Year: 2019-2021
Key parameters: Outcome after BTKi-failure, Health care utilization
Type of analysis: Aggregated
Publication: DOI: 10.1111/bjh.18519
Long-term outcomes of first relapsed-refractory younger patients with mantle-cell lymphoma: the late-POD project
Status: Completed
Type, Partner: Academic, FIL (Visco) and EMCL Network
Year: 2020-2024
Key parameters: Patients with positive disease course - characteristics
Type of analysis: Aggregated
Publication: DOI: 10.1182/blood.2023023525
Outcome of COVID-19 in patients with Mantle Cell Lymphoma – Report from the European EMCL registry
Status: Completed
Type, Partner: Academic, EMCL Network
Year: 2021-2022
Key parameters: Outcome of Covid-19- in patients with mantle cell lymphoma
Type of analysis: Aggregated
Publication: DOI: 10.1097/HS9.0000000000000711
Retrospective analysis of real-world treatment patterns in Mantle Cell Lymphoma patients in Germany
Status: Completed
Type, Partner: Entity, AbbVie
Year: 2021-2023
Type of analysis: Aggregated
Secondary data analysis of the EMCL registry to evaluate characteristics, treatment patterns and outcomes of BTKi pre-treated MCL patients
Status: Completed
Type, Partner: Entity, Lilly-GER
Year: 2022-2024
Type of analysis: Aggregated
A non-interventional, retrospective registry data analysis (descriptive) leveraging real-world data from the multi-centre MCL registry, on patients who started 1L treatment between 1st January 2016 and 31st December 2021 in Germany, Italy and Europe
Status: Completed
Type, Partner: Entity, Janssen
Year: 2022-2023
Type of analysis: Aggregated
